Cerba HealthCare

Cerba HealthCare

Cerba HealthCare is a medical diagnostics group headquartered in Issy-les-Moulineaux, France. The company operates across the clinical pathology value chain, offering routine biology testing, specialty diagnostics, and clinical trial laboratory services through a network of labs and patient service centers, primarily in Europe and Africa. EQT acquired a majority stake in the business in 2017, and the firm has remained under private equity ownership through subsequent transitions. The group builds market density through acquisitions of independent laboratories, connecting local patient-service points to centralized, high-throughput specialty hubs. Its service mix includes routine blood and urine analysis, anatomic pathology, genetics, microbiology, and companion diagnostics for oncology and immunology. Cerba's clinical trials division, Cerba Research, extends the model into biopharma logistics, supporting decentralized trials and biomarker analysis. Geographic coverage concentrates on France, Belgium, and Luxembourg, with a growing African footprint through the Cerba Lancet Africa joint venture established in 2019. Cerba HealthCare processes tens of millions of tests annually and has expanded through dozens of bolt-on acquisitions under EQT and subsequent sponsor ownership. The company's laboratory network is supplemented by specialty reference centers in immunology, molecular biology, and pathology. In September 2024, EQT and PSP Investments agreed to acquire a co-controlling stake in the business from existing owners, a transaction that valued the group near the reported enterprise-level figures for the European lab consolidator space. The structural distinction of Cerba HealthCare lies in its hub-and-spoke model — routine sample collection occurs at local patient centers while high-complexity analysis is concentrated in specialized reference facilities. This architecture allows the group to serve both community-based physicians and centralized clinical trial sponsors without the capital redundancy of fully independent labs, creating a durable operational moat in a sector where regulatory licensing and physician relationships raise natural barriers to entry.